



THE
BLADDER CANCER
COMPANY

Photocure ASA: Invitation to presentation of 4th quarter and preliminary full year 2023 financial results

Oslo, Norway, 19 February 2024: Photocure ASA (Photocure, PHO: OSE) will announce the fourth quarter and preliminary full year 2023 financial results on Wednesday 21 February 2024 at 08:00 CET and will present a live webcast at 14:00 CET the same day.

The quarterly report and presentation will be published at 08:00 CET and will be publicly available at www.photocure.com.

The investor presentation will be streamed live and be hosted by Dan Schneider, CEO and Erik Dahl, CFO. The presentation will be held in English and questions can be submitted throughout the event. The presentation is scheduled to conclude at 14:45 CET.

The streaming event is available through http://channel.royalcast.com/landingpage/hegnarmedia/20240221_5/

For further information, please contact:

Photocure

Erik Dahl
CFO
Tel: +47 45055000
Email: ed@photocure.com

David Moskowitz
Vice President, Investor Relations
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com

Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

About Photocure

Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives

of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.hexvix.com, www.cysview.com

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.